-
公开(公告)号：US20210283138A1
公开(公告)日：2021-09-16
申请号：US16081709
申请日：2017-03-03
Applicant: Vanderbilt University
Inventor： Taekyu Lee , James C. Tarr , KyuOk Jeon , James M. Salovich , Subrata Shaw , Nagarathanam Veerasamy , Kwangho Kim , Plamen P. Christov , Edward T. Olejniczak , Bin Zhao , Stephen W. Fesik , Zhiguo Bian
IPC: A61K31/551 , A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377 , A61K31/538 , A61K31/506 , C07D519/00 , C07D403/04 , C07D403/14 , C07D401/14 , A61P35/00
Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
-
公开(公告)号：US20230039309A1
公开(公告)日：2023-02-09
申请号：US17518732
申请日：2021-11-04
Applicant: Vanderbilt University
Inventor： Taekyu Lee , Zhiguo Bian , Johannes Belmar , Plamen P. Christov , Nicholas F. Pelz , Subrata Shaw , Kwangho Kim , James C. Tarr , Edward T. Olejniczak , Bin Zhao , Stephen W. Fesik
IPC: C07D487/04 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/14 , C07D209/42 , A61K31/551 , A61K31/381 , A61K31/4045 , A61K31/498 , C07D409/14 , C07D471/04 , C07D409/12 , A61K31/404 , A61K31/4155 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14
Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
-
公开(公告)号：US20180258039A1
公开(公告)日：2018-09-13
申请号：US15975854
申请日：2018-05-10
Applicant: Vanderbilt University
Inventor： Taekyu Lee , Kwangho Kim , Plamen P. Christov , Johannes Belmar , Jason P. Burke , Edward T. Olejniczak , Stephen W. Fesik
IPC: C07D209/26 , C07D209/24 , C07D413/04 , C07D403/04 , C07D401/04 , C07D401/14 , A61K31/5377 , A61K31/4045 , A61K31/404 , A61K31/4155 , A61K31/422 , A61K31/4439 , A61K45/06
CPC classification number: C07D209/26 , A61K31/404 , A61K31/4045 , A61K31/4155 , A61K31/422 , A61K31/4439 , A61K31/5377 , A61K45/06 , C07D209/24 , C07D401/04 , C07D401/14 , C07D403/04 , C07D413/04
Abstract: The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.
-
公开(公告)号：US10005728B2
公开(公告)日：2018-06-26
申请号：US14914307
申请日：2014-08-28
Applicant: Vanderbilt University
Inventor： Taekyu Lee , Kwangho Kim , Plamen P. Christov , Johannes Belmar , Jason P. Burke , Edward T. Olejniczak , Stephen W. Fesik
IPC: C07D209/26 , A61K31/4045 , C07D401/14 , C07D401/04 , C07D403/04 , C07D413/04 , C07D209/24 , A61K31/404 , A61K31/4155 , A61K31/422 , A61K31/4439 , A61K31/5377 , A61K45/06
CPC classification number: C07D209/26 , A61K31/404 , A61K31/4045 , A61K31/4155 , A61K31/422 , A61K31/4439 , A61K31/5377 , A61K45/06 , C07D209/24 , C07D401/04 , C07D401/14 , C07D403/04 , C07D413/04
Abstract: The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.
-
5.发明申请公开(公告)号：US20150336925A1
公开(公告)日：2015-11-26
申请号：US14429799
申请日：2013-09-20
Applicant: VANDERBILT UNIVERSITY
Inventor： Taekyu Lee , Nicholas F. Pelz , Johannes Belmar , Zhiguo Bian , Edward T. Olejniczak , Stephen W. Fesik , Brian A. Chauder
IPC: C07D333/70 , C07D307/85 , C07D401/12 , C07D405/10 , C07D413/10 , C07D401/10 , C07D401/14 , C07D405/12 , A61K31/381 , A61K31/343 , A61K31/404 , A61K31/4709 , A61K31/422 , A61K31/4439 , A61K31/4155 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D209/42
CPC classification number: C07D307/85 , A61K31/343 , A61K31/381 , A61K31/404 , A61K31/4155 , A61K31/422 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D209/42 , C07D333/70 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/10 , C07D413/12 , C07D471/04
Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
Abstract translation: 本发明提供抑制抗凋亡Bcl-2家族成员骨髓细胞白血病-1（Mcl-1）蛋白的活性的化合物。 本发明还提供药物组合物以及使用化合物治疗特征在于Mcl-1蛋白过度表达或失调的疾病和病症（例如癌症）的方法。
-
Patent Agency Ranking
公开(公告)号：US10533010B2
公开(公告)日：2020-01-14
申请号：US15129042
申请日：2015-03-26
Applicant: Vanderbilt University
Inventor： Taekyu Lee , Zhiguo Bian , Johannes Belmar , Plamen P. Christov , Nicholas F. Pelz , Subrata Shaw , Kwangho Kim , James C. Tarr , Edward T. Olejniczak , Bin Zhao , Stephen W. Fesik
IPC: C07D487/04 , A61K31/381 , A61K31/4045 , A61K31/498 , A61K31/551 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/14 , C07D409/12 , C07D409/14 , C07D471/04 , C07D209/42 , A61K31/404 , A61K31/4155 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14
Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
-
公开(公告)号：US20190084988A1
公开(公告)日：2019-03-21
申请号：US16135729
申请日：2018-09-19
Applicant: Vanderbilt University
Inventor： Stephen W. Fesik , Shaun R. Stauffer , James M. Salovich , William P. Tansey , Feng Wang , Jason Phan , Edward T. Olejniczak
IPC: C07D487/04 , A61P35/02
Abstract: Described are N-(6-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-2,3-dihydro-1H-inden-1-yl)benzamide and acetamide-containing compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
-
公开(公告)号：US20180312485A1
公开(公告)日：2018-11-01
申请号：US16025768
申请日：2018-07-02
Applicant: Vanderbilt University
Inventor： Taekyu Lee , Nicholas F. Pelz , Johannes Belmar , Zhiguo Bian , Edward T. Olejniczak , Stephen W. Fesik , Brian A. Chauder
IPC: C07D307/85 , A61K31/5377 , C07D401/14 , A61K31/4155 , A61K31/4439 , A61K31/422 , A61K31/4709 , A61K31/404 , A61K31/343 , A61K31/381 , C07D401/10 , C07D413/10 , C07D405/10 , A61K45/06 , C07D471/04 , C07D413/12 , C07D413/04 , C07D409/04 , C07D405/04 , C07D403/14 , C07D403/04 , C07D401/06 , C07D401/04 , C07D405/14 , C07D403/12 , C07D209/42 , C07D405/12 , C07D401/12 , C07D333/70 , A61K31/496
CPC classification number: C07D307/85 , A61K31/343 , A61K31/381 , A61K31/404 , A61K31/4155 , A61K31/422 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D209/42 , C07D333/70 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/10 , C07D413/12 , C07D471/04
Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
-
公开(公告)号：US20170174689A1
公开(公告)日：2017-06-22
申请号：US15129042
申请日：2015-03-26
Applicant: Vanderbilt University
Inventor： Taekyu Lee , Zhiguo Bian , Johannes Belmar , Plamen P. Christov , Nicholas F. Pelz , Subrata Shaw , Kwangho Kim , James C. Tarr , Edward T. Olejniczak , Bin Zhao , Stephen W. Fesik
IPC: C07D487/04 , A61K31/404 , A61K45/06 , C07D401/12 , A61K31/4439 , C07D403/04 , A61K31/4155 , A61K31/4985 , A61K31/551 , C07D403/14 , C07D401/04 , C07D403/12 , A61K31/496 , A61K31/5377 , A61K31/454 , C07D405/12 , C07D405/14 , C07D401/14 , A61K31/4725 , C07D209/42
CPC classification number: C07D487/04 , A61K31/381 , A61K31/404 , A61K31/4045 , A61K31/4155 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K45/06 , C07D209/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D471/04
Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
-
公开(公告)号：US12195472B2
公开(公告)日：2025-01-14
申请号：US17518732
申请日：2021-11-04
Applicant: Vanderbilt University
Inventor： Taekyu Lee , Zhiguo Bian , Johannes Belmar , Plamen P. Christov , Nicholas F. Pelz , Subrata Shaw , Kwangho Kim , James C. Tarr , Edward T. Olejniczak , Bin Zhao , Stephen W. Fesik
IPC: C07D487/04 , A61K31/381 , A61K31/404 , A61K31/4045 , A61K31/4155 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K45/06 , C07D209/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D471/04
Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.038 seconds)
